LinkBack URL
About LinkBacks
Reply With QuoteI first bought ctic in Feb and have added shares to my account twice since.
CTIC LONG
CTIC - Cell Therapeutics Inc. (NASDAQ)
CTIC focuses on the development, acquisition and commercialization of drugs for the treatment of cancer. They are awaiting an FDA approval for the drug PIXANTRONE to treat relapsed or refractory, aggressive non-Hodgkin’s lymphoma (NHL). They NDA (New Drug Application) was submitted 02/07/2009 and CTIC could see an FDA decision the 4th quarter of 2009.
Pixantrone is currently available in Europe on a named-patient basis. This is a good sign as this proves the drug is at least safe enough to use for some patients before approval.
06/03/2009 Cell Therapeutics Says Brown Uty. Study Reveals High Pathological Complete Response Rate for OPAXIO Treatment in Esophagus Cancer - Update
RTTNews - Latest Earnings,Upcoming Earnings, Pos Pre Announcements, Pos Pre Announcements , Positive Surprises, Negative Surprises, Hot Stocks, Stock Split Calendar, Stock Buybacks, Dividends, Negative, Positive PreAnnouncements,Surprises ....
Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With
CTIC *************: Watch Cell Therapeutics, Inc.(NASDAQ:CTIC) After Cancer Study News
06/30/2009 - CTIC was added to Russell 3000(R) and Russell 2000(R)
With the approval of pixantrone I believe this will skyrocket. This drug has a huge potential market and so far seems to be safe and effective.
Cell Therapeutics, Inc.
501 Elliott Avenue West
Suite 400
Seattle, WA 98119
United States - Map
Phone: 206-282-7100
Fax: 206-284-6206
Web Site: http://www.cticseattle.com
Last edited by FavStocks; 07-07-2009 at 09:08 PM. Reason: using new chart
Holding strong!
I first bought ctic in Feb and have added shares to my account twice since.
CTIC LONG
Very nice entry point! What brought your attention to CTIC in Feb?
Ctic long
It was listed as bullish under yahoo community sentiment. Did some research and bought it as a speculative play. A week later it went down to 5 cents and I thought I picked another loser. Held on and now I am VERY happy I did.
CTIC is expecting OPAXIO approval in the next couple weeks or so right? What do you expect are the chances of approval?
Barkmandog: I always wondered how that Yahoo bullish section is upddated. Is it a manual thing you think or is it based on message board activity and stock price direction?
European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.'s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application
Potential regulatory approval decision in Q4-2009
Press Release
Source: Cell Therapeutics, Inc.
On Tuesday July 7, 2009, 1:30 am EDT
Buzz up! 0
Companies: Cell therapeutics, inc.
SEATTLE, July 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it had requested and the EMEA has agreed to an oral explanation in support of the OPAXIO Marketing Authorization Application (MAA) in September, 2009 extending the review for the Committee for Medicinal Products for Human Use (CHMP) opinion on approval until Q4-2009. In April, 2008 the EMEA accepted for review the MAA for OPAXIO for first-line treatment of patients with advanced non-small cell lung cancer who are performance status 2, based on a non-inferior survival and improved side effect profile. The previously scheduled June, 2009 meeting with the EMEA on OPAXIO did not occur due to conflicts in regulatory schedule as CTI focused on completing the pixantrone New Drug Application (NDA) submission in June, 2009.
Related Quotes
Symbol Price Change
CTIC 1.54 -0.06
"We are pleased that the EMEA has agreed to an in person oral explanation in September allowing the Company and its lung cancer experts adequate time to prepare a thorough review for the Co-rapporteurs in support of our MAA for OPAXIO in non-small cell lung cancer," said James A. Bianco, M.D., CEO of Cell Therapeutics. "The fourth quarter is shaping up to be a pivotal period for the Company."
About OPAXIO(TM)
OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that OPAXIO metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.
European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.'s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application - Yahoo! Finance
Hopefully near the end of July we will hear if pixatrone gets fast track status.
ctic long
i got in late december.i found it on a wamu board
Adam Fuerstein
"My price target for Cell Therapeutics: 20 to 30 cents a share. "
Biotech Stock Mailbag: Spectrum | Page 3 of 5 | Biotech | Financial Articles & Investing News | TheStreet.com
Posting Permissions 